RU2498988C2 - Ингибиторы активности протеинтирозинкиназы - Google Patents

Ингибиторы активности протеинтирозинкиназы Download PDF

Info

Publication number
RU2498988C2
RU2498988C2 RU2010145459/04A RU2010145459A RU2498988C2 RU 2498988 C2 RU2498988 C2 RU 2498988C2 RU 2010145459/04 A RU2010145459/04 A RU 2010145459/04A RU 2010145459 A RU2010145459 A RU 2010145459A RU 2498988 C2 RU2498988 C2 RU 2498988C2
Authority
RU
Russia
Prior art keywords
tyrosine kinase
protein tyrosine
compound according
connection
kinase activity
Prior art date
Application number
RU2010145459/04A
Other languages
English (en)
Other versions
RU2010145459A (ru
Inventor
Майкл МАННИОН
Стефан Раппель
Стивен Уилльям КЛАРИДЖ
Фредерик Годетт
Лицзи ЧЖАНЬ
Любомир ИСАКОВИЦ
Оскар Марио СААВЕДРА
Тетсуюки УНО
Масаши КИШИДА
Аркадий Вайсбург
Original Assignee
Метилджин, Инк.
Одзука Фармасьютикал Ко. Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Метилджин, Инк., Одзука Фармасьютикал Ко. Лтд. filed Critical Метилджин, Инк.
Publication of RU2010145459A publication Critical patent/RU2010145459A/ru
Application granted granted Critical
Publication of RU2498988C2 publication Critical patent/RU2498988C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Изобретение относится к органической химии, а именно к соединениям следующих формул
Figure 00000181
Figure 00000182
Figure 00000183
Figure 00000184
Изобретение также относится к фармацевтической композиции, обладающей ингибирующей активностью в отношении протеинтирозинкиназы, на основе указанных соединений. Технический результат: получены новые соединения, которые могут найти применение в медицине для лечения офтальмологических заболеваний, нарушений и патологических состояний. 3 н. и 8 з.п. ф-лы, 7 табл., 223 пр.

Description

Текст описания приведен в факсимильном виде.
Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067
Figure 00000068
Figure 00000069
Figure 00000070
Figure 00000071
Figure 00000072
Figure 00000073
Figure 00000074
Figure 00000075
Figure 00000076
Figure 00000077
Figure 00000078
Figure 00000079
Figure 00000080
Figure 00000081
Figure 00000082
Figure 00000083
Figure 00000084
Figure 00000085
Figure 00000086
Figure 00000087
Figure 00000088
Figure 00000089
Figure 00000090
Figure 00000091
Figure 00000092
Figure 00000093
Figure 00000094
Figure 00000095
Figure 00000096
Figure 00000097
Figure 00000098
Figure 00000099
Figure 00000100
Figure 00000101
Figure 00000102
Figure 00000103
Figure 00000104
Figure 00000105
Figure 00000106
Figure 00000107
Figure 00000108
Figure 00000109
Figure 00000110
Figure 00000111
Figure 00000112
Figure 00000113
Figure 00000114
Figure 00000115
Figure 00000116
Figure 00000117
Figure 00000118
Figure 00000119
Figure 00000120
Figure 00000121
Figure 00000122
Figure 00000123
Figure 00000124
Figure 00000125
Figure 00000126
Figure 00000127
Figure 00000128
Figure 00000129
Figure 00000130
Figure 00000131
Figure 00000132
Figure 00000133
Figure 00000134
Figure 00000135
Figure 00000136
Figure 00000137
Figure 00000138
Figure 00000139
Figure 00000140
Figure 00000141
Figure 00000142
Figure 00000143
Figure 00000144
Figure 00000145
Figure 00000146
Figure 00000147
Figure 00000148
Figure 00000149
Figure 00000150
Figure 00000151
Figure 00000152
Figure 00000153
Figure 00000154
Figure 00000155
Figure 00000156
Figure 00000157
Figure 00000158
Figure 00000159
Figure 00000160
Figure 00000161
Figure 00000162
Figure 00000163
Figure 00000164
Figure 00000165
Figure 00000166
Figure 00000167
Figure 00000168
Figure 00000169
Figure 00000170
Figure 00000171
Figure 00000172
Figure 00000173
Figure 00000174
Figure 00000175

Claims (11)

1. Соединение, выбранное из группы, включающей:
Figure 00000176
,
Figure 00000177
,
Figure 00000178
,
Figure 00000179
,
и его фармацевтически приемлемые соли или сольваты.
2. Соединение по п.1, которое представляет собой
Figure 00000176
.
3. Соединение по п.1, которое представляет собой
Figure 00000177
.
4. Соединение по п.1, которое представляет собой
Figure 00000178
.
5. Соединение по п.1, которое представляет собой
Figure 00000179
.
6. Фармацевтическая композиция, обладающая ингибирующей активностью в отношении протеинтирозинкиназы, содержащая соединение по любому из пп.1-5 и фармацевтически приемлемый носитель.
7. Способ лечения офтальмологического заболевания, патологического состояния или нарушения, включающий введение нуждающемуся в этом пациенту соединения по любому из пп.1-5 или содержащей его композиции в терапевтически эффективном количестве.
8. Способ по п.7, в котором соединением является
Figure 00000176
.
9. Способ по п.7, в котором соединением является
Figure 00000177
.
10. Способ по п.7, в котором соединением является
Figure 00000178
.
11. Способ по п.7, в котором соединением является
Figure 00000180
.
RU2010145459/04A 2008-03-05 2009-02-27 Ингибиторы активности протеинтирозинкиназы RU2498988C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3400508P 2008-03-05 2008-03-05
US61/034,005 2008-03-05

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2010140668/04A Division RU2533827C2 (ru) 2008-03-05 2009-02-27 Ингибиторы активности протеинтирозинкиназы

Publications (2)

Publication Number Publication Date
RU2010145459A RU2010145459A (ru) 2012-05-20
RU2498988C2 true RU2498988C2 (ru) 2013-11-20

Family

ID=41055503

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2010140668/04A RU2533827C2 (ru) 2008-03-05 2009-02-27 Ингибиторы активности протеинтирозинкиназы
RU2010145459/04A RU2498988C2 (ru) 2008-03-05 2009-02-27 Ингибиторы активности протеинтирозинкиназы

Family Applications Before (1)

Application Number Title Priority Date Filing Date
RU2010140668/04A RU2533827C2 (ru) 2008-03-05 2009-02-27 Ингибиторы активности протеинтирозинкиназы

Country Status (19)

Country Link
US (3) US8729268B2 (ru)
EP (2) EP2262815A4 (ru)
JP (2) JP2011513339A (ru)
KR (2) KR20100137495A (ru)
CN (2) CN102161663B (ru)
AR (2) AR070539A1 (ru)
AU (2) AU2009221583B2 (ru)
BR (2) BRPI0923670A2 (ru)
CA (2) CA2763168A1 (ru)
CO (1) CO6290684A2 (ru)
IL (2) IL207946A0 (ru)
MX (1) MX2010009729A (ru)
NZ (2) NZ589336A (ru)
RU (2) RU2533827C2 (ru)
SG (1) SG182146A1 (ru)
TW (2) TW200940549A (ru)
UA (2) UA100262C2 (ru)
WO (1) WO2009109035A1 (ru)
ZA (2) ZA201005868B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200940549A (en) * 2008-03-05 2009-10-01 Methylgene Inc Inhibitors of protein tyrosine kinase activity
KR20120047313A (ko) 2009-09-03 2012-05-11 알러간, 인코포레이티드 티로신 키나제 조절인자로서의 화합물
US9340555B2 (en) 2009-09-03 2016-05-17 Allergan, Inc. Compounds as tyrosine kinase modulators
KR20130100234A (ko) * 2010-04-16 2013-09-10 메틸진 인코포레이티드 단백질 티로신 키나아제 활성의 억제 및 안구 질환을 치료하는 이의 용도
TWI482770B (zh) * 2010-06-09 2015-05-01 Abbvie Bahamas Ltd 結晶型激酶抑制劑
WO2011156473A1 (en) * 2010-06-09 2011-12-15 Abbott Laboratories Crystalline forms of kinase inhibitors
TWI492949B (zh) * 2010-06-09 2015-07-21 Abbvie Bahamas Ltd 結晶型激酶抑制劑
MX2013002199A (es) * 2010-08-27 2013-03-18 Merck Patent Gmbh Derivados de furopiridina.
AU2011303597A1 (en) * 2010-09-17 2013-04-11 Purdue Pharma L.P. Pyridine compounds and the uses thereof
BRPI1004176A2 (pt) * 2010-10-25 2015-08-11 Univ Rio De Janeiro Compostos aril e/ou hetero aril uréias funcionalizados; processo de síntese desses composto; composição farmacêutica contendo tais compostos e usos
WO2013044362A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Selected inhibitors of protein tyrosine kinase activity
WO2013044360A1 (en) * 2011-09-30 2013-04-04 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
US20130096088A1 (en) * 2011-09-30 2013-04-18 Methylgene Inc. Inhibitors of Protein Tyrosine Kinase Activity
MX2017007629A (es) * 2014-12-09 2018-05-17 Abbvie Inc Compuestos inhibidores de bcl-xl que tienen una baja permeabilidad en las celulas y conjugados de anticuerpo-farmaco que los incluyen.
FR3037957B1 (fr) * 2015-06-23 2019-01-25 Les Laboratoires Servier Nouveaux derives d'hydroxyester, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MX2020008016A (es) 2018-01-31 2020-11-09 Deciphera Pharmaceuticals Llc Terapia de combinación para el tratamiento de tumores del estroma gastrointestinal.
BR112022002609A2 (pt) 2019-08-12 2022-08-09 Deciphera Pharmaceuticals Llc Métodos de tratamento de tumores estromais gastrointestinais
TW202122082A (zh) 2019-08-12 2021-06-16 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
FI4084778T3 (fi) 2019-12-30 2023-12-18 Deciphera Pharmaceuticals Llc Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi
AU2020417282B2 (en) 2019-12-30 2023-08-31 Deciphera Pharmaceuticals, Llc Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea
TW202342426A (zh) * 2022-02-15 2023-11-01 大陸商百濟神州（蘇州）生物科技有限公司 N-[(6-溴吡啶-3-基)甲基]-2-甲氧基乙烷-1-胺鹽及其製備方法
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005120018A (ru) * 2002-11-25 2006-05-10 Уайт (Us) Тиено {3,2-b} пиридин-6-карбонитрилы и тиено {2,3-b} пиридин -5-карбонитрилы в качестве ингибиторов протеинкиназы
CA2611370A1 (en) * 2005-05-20 2006-11-20 Oscar Mario Saavedra Inhibitors of vegf receptor and hgf receptor signaling

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7000A (en) * 1850-01-08 Smut-machine
US7019A (en) * 1850-01-15 Improvement in obstetrical supporters
US6107300A (en) 1996-03-27 2000-08-22 Dupont Pharmaceuticals Arylamino fused pyrimidines
ID23978A (id) 1997-11-11 2000-06-14 Pfizer Prod Inc Turunan-turunan tienopirimidin dan tienopiridin yang berguna sebagai zat-zat anti kangker
US6232320B1 (en) 1998-06-04 2001-05-15 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
PL345906A1 (en) 1998-06-04 2002-01-14 Abbott Lab Cell adhesion-inhibiting antinflammatory compounds
EP1181296A1 (en) 1999-06-03 2002-02-27 Abbott Laboratories Cell adhesion-inhibiting antiinflammatory compounds
MXPA02012034A (es) 2000-06-06 2003-04-25 Pfizer Prod Inc Derivados de tiofeno utiles como agentes anticancerosos.
US20020004511A1 (en) 2000-06-28 2002-01-10 Luzzio Michael Joseph Thiophene derivatives useful as anticancer agents
AU2001295986B2 (en) * 2000-10-20 2006-08-17 Eisai R&D Management Co., Ltd Nitrogenous aromatic ring compounds
WO2003000194A2 (en) 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
CA2478050A1 (en) 2002-03-01 2003-09-12 Pfizer Inc. Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
US20030199525A1 (en) 2002-03-21 2003-10-23 Hirst Gavin C. Kinase inhibitors
WO2005009348A2 (en) 2003-06-25 2005-02-03 Ariad Pharmaceuticals, Inc. Substituted purine derivatives
JP2007504122A (ja) 2003-08-29 2007-03-01 ファイザー・インク 新規抗血管形成剤として有用なチエノピリジン−フェニルアセトアミドおよびその誘導体
US7581674B2 (en) 2003-11-21 2009-09-01 Charles Cohen Financial transaction system and method
JP2007518823A (ja) 2004-01-23 2007-07-12 アムゲン インコーポレイテッド キノリン、キナゾリン、ピリジン、及びピリミジン化合物と炎症、血管新生、及び癌に対する治療におけるそれら化合物の用途
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
WO2005121125A1 (en) 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
US7173031B2 (en) 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
EP1773826A4 (en) 2004-07-02 2009-06-03 Exelixis Inc MODULATORS OF C-MET AND THEIR METHOD OF USE
CA2573999A1 (en) 2004-07-16 2006-04-06 Sunesis Pharmaceuticals, Inc. Thienopyrimidines useful as aurora kinase inhibitors
ES2438017T3 (es) 2004-07-30 2014-01-15 Methylgene Inc. Inhibidores de la señalización del receptor del VEGF y del receptor del HGF
JP2008521900A (ja) 2004-11-30 2008-06-26 アムジエン・インコーポレーテツド キノリン及びキナゾリン類似体並びにがん治療のための医薬としてのその使用
AU2006229343A1 (en) * 2005-03-28 2006-10-05 Kirin Pharma Kabushiki Kaisha Thienopyridine derivative, or quinoline derivative, or quinazoline derivative, having c-Met autophosphorylation inhibiting potency
EP1874759A4 (en) 2005-04-06 2009-07-15 Exelixis Inc C-MET MODULATORS MODULATORS AND METHODS OF USE
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
JP5275792B2 (ja) 2005-05-20 2013-08-28 メチルジーン インコーポレイテッド Ｖｅｇｆレセプターおよびｈｇｆレセプターシグナル伝達の阻害剤
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
US8003662B2 (en) * 2006-01-30 2011-08-23 Array Biopharma, Inc. Heterobicyclic thiophene compounds and methods of use
WO2007107005A1 (en) 2006-03-22 2007-09-27 Methylgene, Inc. Inhibitors of protein tyrosine kinase activity
US7298968B1 (en) * 2007-01-05 2007-11-20 Rheem Manufacturing Company Pumpless combination instantaneous/storage water heater system
RU2495044C2 (ru) * 2007-08-29 2013-10-10 Метилджен Инк. Ингибиторы активности протеинтирозинкиназы
TW200940549A (en) * 2008-03-05 2009-10-01 Methylgene Inc Inhibitors of protein tyrosine kinase activity
KR20130100234A (ko) * 2010-04-16 2013-09-10 메틸진 인코포레이티드 단백질 티로신 키나아제 활성의 억제 및 안구 질환을 치료하는 이의 용도

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2005120018A (ru) * 2002-11-25 2006-05-10 Уайт (Us) Тиено {3,2-b} пиридин-6-карбонитрилы и тиено {2,3-b} пиридин -5-карбонитрилы в качестве ингибиторов протеинкиназы
CA2611370A1 (en) * 2005-05-20 2006-11-20 Oscar Mario Saavedra Inhibitors of vegf receptor and hgf receptor signaling

Also Published As

Publication number Publication date
KR20100132068A (ko) 2010-12-16
EP2262815A1 (en) 2010-12-22
RU2010140668A (ru) 2012-04-10
NZ588355A (en) 2012-03-30
US20140179632A1 (en) 2014-06-26
AU2009221583A1 (en) 2009-09-11
IL207946A0 (en) 2010-12-30
CN102161663B (zh) 2014-03-19
AU2010246540B2 (en) 2013-02-28
CN102161663A (zh) 2011-08-24
UA101362C2 (en) 2013-03-25
TW200940549A (en) 2009-10-01
AR070539A1 (es) 2010-04-14
ZA201005868B (en) 2011-08-31
EP2262815A4 (en) 2012-04-11
RU2533827C2 (ru) 2014-11-20
JP2011513339A (ja) 2011-04-28
CA2717816A1 (en) 2009-09-11
JP2011105735A (ja) 2011-06-02
TW201113288A (en) 2011-04-16
RU2010145459A (ru) 2012-05-20
US8729268B2 (en) 2014-05-20
EP2332536A1 (en) 2011-06-15
TWI438205B (zh) 2014-05-21
CN102015723B (zh) 2014-07-30
AU2010246540A1 (en) 2010-12-23
WO2009109035A1 (en) 2009-09-11
BRPI0908573A2 (pt) 2012-12-25
US20110077240A1 (en) 2011-03-31
US8759522B2 (en) 2014-06-24
KR20100137495A (ko) 2010-12-30
CO6290684A2 (es) 2011-06-20
IL208882A0 (en) 2011-07-31
NZ589336A (en) 2011-12-22
MX2010009729A (es) 2010-12-21
CN102015723A (zh) 2011-04-13
AU2009221583B2 (en) 2013-06-20
SG182146A1 (en) 2012-07-30
AU2009221583A2 (en) 2011-02-03
BRPI0923670A2 (pt) 2013-07-30
UA100262C2 (ru) 2012-12-10
CA2763168A1 (en) 2009-09-11
ZA201007517B (en) 2012-01-25
US20110098293A1 (en) 2011-04-28
AR079208A2 (es) 2012-01-04
JP5661485B2 (ja) 2015-01-28

Similar Documents

Publication Publication Date Title
RU2498988C2 (ru) Ингибиторы активности протеинтирозинкиназы
RU2416611C2 (ru) Бициклические амиды как ингибиторы киназы
RU2401658C2 (ru) Гетероциклические ингибиторы аспартилпротеазы
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
EA200601239A1 (ru) Замещённые хинолиновые соединения
EA200501607A1 (ru) Замещённые фенилалкановые кислоты
MA38380A1 (fr) Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr)
EA201270666A1 (ru) Соединения и фармацевтические композиции для снижения уровня мочевой кислоты
EA200900152A1 (ru) Ингибиторы пирролотриазинкиназы
EA200601212A1 (ru) Ингибиторы фосфодиэстеразы, получение и их терапевтическое применение
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA200971041A1 (ru) Новые пептидные ингибиторы репликации вируса гепатита с
EA201500266A1 (ru) Ингибиторы репликации вирусов гриппа
MA28935B1 (fr) Preparation et utilisation de derives de biphenyl-4-yl-carbonylamino-acide dans le traitement de l'obesite
BRPI0606690A2 (pt) composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica
EA201400111A1 (ru) Ингибиторы mek и способы их применения
EP1841426A4 (en) TERTIARY CARBINAMINES INCLUDING SUBSTITUTED HETEROCYCLES AS BETA SECRETASE INHIBITORS AND FOR THE TREATMENT OF ALZHEIMER'S DISEASE
ATE538651T1 (de) Spiropiperidininhibitoren von beta-secretase zur behandlung von alzheimer-krankheit
EA200601846A1 (ru) Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей
EA201490163A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201100873A1 (ru) Пиридилоксииндолы - ингибиторы vegf-r2 и их применение для лечения заболевания
ATE396973T1 (de) Benzylether- und benzylamino-beta-sekretase- hemmer zur behandlung von alzheimer-krankheit
BRPI0713755A8 (pt) composto ou um sal ou solvato do mesmo, uso do composto ou um sal ou salvato do mesmo, composição farmacêutica,e, processo para a preparação de um composto ou um sal ou solvato do mesmo
WO2006044497A3 (en) Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease
EA201391786A1 (ru) Галоген-алкил-1,3-оксазины в качестве ингибиторов bace1 и/или bace2

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20150228